FDA/CDC

FDA advisory committee recommends volanesorsen for rare triglyceride disorder


 

REPORTING FROM an fda advisory committee meeting

The FDA is expected to decide on the application by August 30. The FDA usually follows the recommendations of its advisory panels, which are not binding.


ilacy@mdedge.com

Pages

Recommended Reading

Statin-associated muscle symptoms? Rechallenge!
MDedge Cardiology
CVD risk high in individuals who once had metabolically healthy obesity
MDedge Cardiology
Psoriasis duration reflects cardiovascular event risk
MDedge Cardiology
Sucralose sparks appetite in obese, not lean, individuals
MDedge Cardiology
MI before age 50? Think familial hypercholesterolemia, substance abuse
MDedge Cardiology
Metabolic syndrome scoring system predicts CVD in type 2 diabetes
MDedge Cardiology
Maternal morbidity and BMI: A dose-response relationship
MDedge Cardiology
Obesity and weight loss both linked to RA disability
MDedge Cardiology
Interventionalists skeptical about public reporting of PCI
MDedge Cardiology
Annual ob.gyn. visit a ‘powerful opportunity’ to talk heart health
MDedge Cardiology